All News

Pharmaceutical Executive

The Office of Prescription Drug Promotion (OPDP) is reorganizing its two primary advertising review divisions – professional and consumer – in an attempt to stay in line with the silo-breaking, multi-channel promotional output pouring in from pharma.

Pharmaceutical Executive

Finding the right people for the right job might seem an afterthought for big Pharma companies that have cut their US workforce by more than 250,000 in the past 10 years.

Pharmaceutical Executive

One of 2012’s biggest buzzwords was “Gamification” and that probably means that in 2013 there are a lot of people trying to sell you on the value of gamifying your pharma business.

Pharmaceutical Executive

The rare disease advocacy community convened yesterday for its annual Rare Disease Day celebration, marking another year of advances in the fight against ailments once almost entirely ignored by big Pharma.

Pharmaceutical Executive

CBI’s 12th Annual Digital Innovation Forum, better known as iPharma, covered a broad range of topics from maintaining salient SEO strategy to effectively managing digital project pipelines across different departments.

PHouston_blog_size.jpg

Pharmaceutical Executive

You probably have bigger calls on your time, but have you given much thought to social media? Not in the abstract corporate communications sense, in a you-the-CEO sense?

SotU2013.jpg

Pharmaceutical Executive

During his fifth State of the Union address, President Obama struck many familiar chords – including a line about ending certain subsidies to pharmaceutical companies – and emphasized, repeatedly, the need to get things done on the policy front.

Pharmaceutical Executive

With the recent release of the Patient Protection Sunshine Act (PPSA), the Center for Medicare and Medicaid Services (CMS) has established reporting requirements to ensure that drug manufacturers properly disclose payments to physicians in areas of research, continuing medical education, etc.

Pharmaceutical Executive

Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure

Pharmaceutical Executive

This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.